Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models
Debra C. Ferguson(AbbVie (United States)), Ingrid B.J. Joseph(Abbott Fund), Joann P. Palma(Abbott Fund), Gerard M. Sullivan(AbbVie (United States)), Marion Refici(Abbott (United States)), Haiying Zhang(Abbott Fund), Hing L. Sham(University of Nottingham Ningbo China), Joy Bauch(Abbott Fund), Saul H. Rosenberg(Abbott Fund), David J. Frost(Abbott Fund), Nan‐Horng Lin(Abbott Fund), Jacqueline M. O’Connor(Abbott Fund), Kennan Marsh(Abbott Fund), Kenneth Jarvis(Abbott Fund), Luis E. Rodrı́guez(Abbott Fund)
Cited by 22
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k